Lasa Supergenerics Limited (NSE:LASA)

Market Cap	513.54M
Revenue (ttm)	1.47B
Net Income (ttm)	-147.57M
Shares Out	50.10M
EPS (ttm)	-2.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,573
Average Volume	26,665
Open	10.13
Previous Close	10.34
Day's Range	10.13 - 10.34
52-Week Range	8.42 - 33.49
Beta	0.17
RSI	32.16
Earnings Date	Aug 12, 2025

About Paycor HCM

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, and halquinol, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 77
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LASA

Financial Performance

In 2024, Lasa Supergenerics's revenue was 1.47 billion, an increase of 41.23% compared to the previous year's 1.04 billion. Losses were -147.57 million, -32.09% less than in 2023.